tiprankstipranks
Revolution Medicines (DE:42Z)
XETRA:42Z
Germany Market
42Z
Revolution Medicines
RESEARCH TOOLSreports

Revolution Medicines (42Z) Stock Forecast & Price Target

16 Followers
See the Price Targets and Ratings of:

42Z Analyst Ratings

Strong Buy
19Ratings
Strong Buy
18 Buy
1 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Revolution
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

42Z Stock 12 Month Forecast

Average Price Target

€190.42
▲(17.18% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is €190.42 with a high forecast of €251.33 and a low forecast of €130.41. The average price target represents a 17.18% change from the last price of €162.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"€31","252":"€252","86.25":"€86.3","141.5":"€141.5","196.75":"€196.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":251.32810968,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€251.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":190.42343112063162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€190.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.41424248,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€130.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,86.25,141.5,196.75,252],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.85,169.65600843692306,176.46201687384615,183.26802531076922,190.0740337476923,196.88004218461538,203.68605062153847,210.49205905846154,217.29806749538463,224.1040759323077,230.9100843692308,237.71609280615385,244.52210124307692,{"y":251.32810968,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.85,164.9710331631255,167.092066326251,169.21309948937653,171.33413265250203,173.45516581562754,175.57619897875304,177.69723214187857,179.81826530500408,181.93929846812958,184.06033163125508,186.1813647943806,188.30239795750612,{"y":190.42343112063162,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.85,160.35494172923077,157.85988345846152,155.3648251876923,152.86976691692308,150.37470864615383,147.8796503753846,145.3845921046154,142.88953383384614,140.39447556307692,137.8994172923077,135.40435902153848,132.90930075076923,{"y":130.41424248,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€251.33Average Price Target€190.42Lowest Price Target€130.41
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on DE:42Z
Gregory Renza
Truist Financial
Truist Financial
€181.37→€199.51
Buy
22.77%
Upside
Reiterated
08/11/26
Revolution Medicines (RVMD) Receives a Buy from Truist Financial
TD Cowen Analyst forecast on DE:42Z
Marc Frahm
TD Cowen
TD Cowen
€177.18
Buy
9.04%
Upside
Reiterated
08/10/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
Wolfe Research Analyst forecast on DE:42Z
Kalpit Patel
Wolfe Research
Wolfe Research
€142.51→€190.01
Buy
16.93%
Upside
Reiterated
08/10/26
Revolution Medicines price target raised to $220 from $165 at Wolfe ResearchRevolution Medicines price target raised to $220 from $165 at Wolfe Research
LifeSci Capital Analyst forecast on DE:42Z
Charles Zhu
LifeSci Capital
LifeSci Capital
€227.15→€251.33
Buy
54.66%
Upside
Reiterated
08/08/26
Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)
J.P. Morgan Analyst forecast on DE:42Z
Brian Cheng
J.P. Morgan
J.P. Morgan
€177.05→€196.05
Buy
20.65%
Upside
Reiterated
08/07/26
Revolution Medicines price target raised to $227 from $205 at JPMorganRevolution Medicines price target raised to $227 from $205 at JPMorgan
Needham Analyst forecast on DE:42Z
Ami Fadia
Needham
Needham
€203.83→€207.28
Buy
27.56%
Upside
Assigned
08/06/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Medtronic (MDT)
Guggenheim Analyst forecast on DE:42Z
Michael Schmidt
Guggenheim
Guggenheim
€202.96→€207.28
Buy
27.56%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $240 from $235 at GuggenheimRevolution Medicines price target raised to $240 from $235 at Guggenheim
Wells Fargo Analyst forecast on DE:42Z
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
€144.23→€207.28
Buy
27.56%
Upside
Assigned
08/06/26
Wells Fargo Gives a Buy Rating to Revolution Medicines (RVMD)
Piper Sandler Analyst forecast on DE:42Z
Kelsey Goodwin
Piper Sandler
Piper Sandler
€148.55→€181.37
Buy
11.61%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Steris (NYSE: STE) and BeOne Medicines (NASDAQ: ONC)
Oppenheimer Analyst forecast on DE:42Z
Jay Olson
Oppenheimer
Oppenheimer
€168.42→€198.64
Buy
22.24%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $230 from $195 at OppenheimerRevolution Medicines price target raised to $230 from $195 at Oppenheimer
Evercore ISI Analyst forecast on DE:42Z
Cory Kasimov
Evercore ISI
Evercore ISI
€190.01→€198.64
Buy
22.24%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $230 from $220 at Evercore ISIRevolution Medicines price target raised to $230 from $220 at Evercore ISI
Stifel Nicolaus Analyst forecast on DE:42Z
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
€185.69
Buy
14.27%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX), Revolution Medicines (NASDAQ: RVMD) and Sight Sciences (NASDAQ: SGHT)
Wedbush Analyst forecast on DE:42Z
Robert Driscoll
Wedbush
Wedbush
€165.91→€173.6
Buy
6.83%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $201 from $192.10 at WedbushRevolution Medicines price target raised to $201 from $192.10 at Wedbush
Bank of America Securities Analyst forecast on DE:42Z
Alec Stranahan
Bank of America Securities
Bank of America Securities
€183.1→€194.33
Buy
19.59%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on DE:42Z
Leonid Timashev
RBC Capital
RBC Capital
€157.19→€175.33
Buy
7.89%
Upside
Reiterated
08/05/26
RBC Capital Sticks to Its Buy Rating for Revolution Medicines (RVMD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on DE:42Z
Gregory Renza
Truist Financial
Truist Financial
€181.37→€199.51
Buy
22.77%
Upside
Reiterated
08/11/26
Revolution Medicines (RVMD) Receives a Buy from Truist Financial
TD Cowen Analyst forecast on DE:42Z
Marc Frahm
TD Cowen
TD Cowen
€177.18
Buy
9.04%
Upside
Reiterated
08/10/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
Wolfe Research Analyst forecast on DE:42Z
Kalpit Patel
Wolfe Research
Wolfe Research
€142.51→€190.01
Buy
16.93%
Upside
Reiterated
08/10/26
Revolution Medicines price target raised to $220 from $165 at Wolfe ResearchRevolution Medicines price target raised to $220 from $165 at Wolfe Research
LifeSci Capital Analyst forecast on DE:42Z
Charles Zhu
LifeSci Capital
LifeSci Capital
€227.15→€251.33
Buy
54.66%
Upside
Reiterated
08/08/26
Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)
J.P. Morgan Analyst forecast on DE:42Z
Brian Cheng
J.P. Morgan
J.P. Morgan
€177.05→€196.05
Buy
20.65%
Upside
Reiterated
08/07/26
Revolution Medicines price target raised to $227 from $205 at JPMorganRevolution Medicines price target raised to $227 from $205 at JPMorgan
Needham Analyst forecast on DE:42Z
Ami Fadia
Needham
Needham
€203.83→€207.28
Buy
27.56%
Upside
Assigned
08/06/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Medtronic (MDT)
Guggenheim Analyst forecast on DE:42Z
Michael Schmidt
Guggenheim
Guggenheim
€202.96→€207.28
Buy
27.56%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $240 from $235 at GuggenheimRevolution Medicines price target raised to $240 from $235 at Guggenheim
Wells Fargo Analyst forecast on DE:42Z
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
€144.23→€207.28
Buy
27.56%
Upside
Assigned
08/06/26
Wells Fargo Gives a Buy Rating to Revolution Medicines (RVMD)
Piper Sandler Analyst forecast on DE:42Z
Kelsey Goodwin
Piper Sandler
Piper Sandler
€148.55→€181.37
Buy
11.61%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Steris (NYSE: STE) and BeOne Medicines (NASDAQ: ONC)
Oppenheimer Analyst forecast on DE:42Z
Jay Olson
Oppenheimer
Oppenheimer
€168.42→€198.64
Buy
22.24%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $230 from $195 at OppenheimerRevolution Medicines price target raised to $230 from $195 at Oppenheimer
Evercore ISI Analyst forecast on DE:42Z
Cory Kasimov
Evercore ISI
Evercore ISI
€190.01→€198.64
Buy
22.24%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $230 from $220 at Evercore ISIRevolution Medicines price target raised to $230 from $220 at Evercore ISI
Stifel Nicolaus Analyst forecast on DE:42Z
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
€185.69
Buy
14.27%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX), Revolution Medicines (NASDAQ: RVMD) and Sight Sciences (NASDAQ: SGHT)
Wedbush Analyst forecast on DE:42Z
Robert Driscoll
Wedbush
Wedbush
€165.91→€173.6
Buy
6.83%
Upside
Reiterated
08/06/26
Revolution Medicines price target raised to $201 from $192.10 at WedbushRevolution Medicines price target raised to $201 from $192.10 at Wedbush
Bank of America Securities Analyst forecast on DE:42Z
Alec Stranahan
Bank of America Securities
Bank of America Securities
€183.1→€194.33
Buy
19.59%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on DE:42Z
Leonid Timashev
RBC Capital
RBC Capital
€157.19→€175.33
Buy
7.89%
Upside
Reiterated
08/05/26
RBC Capital Sticks to Its Buy Rating for Revolution Medicines (RVMD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

3 Months
Joseph CatanzaroMizuho Securities
Success Rate
12/14 ratings generated profit
86%
Average Return
+25.34%
Copying Joseph Catanzaro's trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +25.34% per trade.
1 Year
Michael SchmidtGuggenheim
Success Rate
18/18 ratings generated profit
100%
Average Return
+108.06%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +108.06% per trade.
2 Years
Alec StranahanBank of America Securities
Success Rate
24/24 ratings generated profit
100%
Average Return
+258.44%
Copying Alec Stranahan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +258.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

42Z Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
7
10
10
6
2
Buy
50
49
64
50
57
Hold
0
1
3
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
60
77
59
62
In the current month, 42Z has received 59 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 42Z average Analyst price target in the past 3 months is 190.42.
Each month's total comprises the sum of three months' worth of ratings.

42Z Financial Forecast

42Z Earnings Forecast

Next quarter’s earnings estimate for 42Z is -€2.12 with a range of -€2.80 to -€1.79. The previous quarter’s EPS was -€2.65. 42Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 42Z has Performed in-line its overall industry.
Next quarter’s earnings estimate for 42Z is -€2.12 with a range of -€2.80 to -€1.79. The previous quarter’s EPS was -€2.65. 42Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 42Z has Performed in-line its overall industry.

42Z Sales Forecast

Next quarter’s sales forecast for 42Z is €6.11M with a range of €0.00 to €43.23M. The previous quarter’s sales results were €0.00. 42Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 42Z has Performed in-line its overall industry.
Next quarter’s sales forecast for 42Z is €6.11M with a range of €0.00 to €43.23M. The previous quarter’s sales results were €0.00. 42Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 42Z has Performed in-line its overall industry.

42Z Stock Forecast FAQ

What is DE:42Z’s average 12-month price target, according to analysts?
Based on analyst ratings, Revolution Medicines’s 12-month average price target is 190.42.
    What is DE:42Z’s upside potential, based on the analysts’ average price target?
    Revolution Medicines has 17.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Revolution Medicines a Buy, Sell or Hold?
          Revolution Medicines has a consensus rating of Strong Buy, which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Revolution Medicines’s share price target?
            The average share price target for Revolution Medicines is 190.42. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €251.33 ,and the lowest forecast is €130.41. The average share price target represents 17.18% Increase from the current price of €162.5.
              What do analysts say about Revolution Medicines?
              Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Revolution Medicines?
                To buy shares of DE:42Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.